Gifts totalling more than £32 million, together with government funds of over £17 million, have enabled the launch of a highly innovative Centre in Cambridge that is pioneering new approaches to understand and treat neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases, motor neurone disease and frontotemporal dementia.
Researchers have manufactured microscopic versions of the cocoons spun by silkworms, which could be used to store sensitive proteins and other molecules for a wide range of uses.
It's over a hundred years since the first case of Alzheimer’s disease was diagnosed. Since then we’ve learned a great deal about the protein ‘tangles’ and ‘plaques’ that cause the disease. How close are we to having effective treatments – and could we even prevent dementia from occurring in the first place?
An approved anti-cancer drug successfully targets the first step in the toxic chain reaction that leads to Alzheimer’s disease, suggesting that treatments may be found to lower the risk of developing the neurodegenerative condition.
New funding will support fundamental research into the molecular processes underlying human disorders such as Alzheimer’s and Parkinson’s diseases, and enable new ways to combat them.
A molecular chaperone has been found to inhibit a key stage in the development of Alzheimer’s disease and break the toxic chain reaction that leads to the death of brain cells, a new study shows. The research provides an effective basis for searching for candidate molecules that could be used to treat the condition.
Conditions which may accelerate the spread of Parkinson’s disease, and a potential means of enhancing naturally-occurring defences against neurodegenerative disorders, have been identified in two new studies.